Disease treatment drug based on mesenchymal-stem-cell mobilization
AssigneesStemrim Inc., Osaka University
InventorsKatsuto Tamai, Takashi Shimbo, Takehiko Yamazaki
Life of this patent
Estimating the term…
Loading patent…
AssigneesStemrim Inc., Osaka University
InventorsKatsuto Tamai, Takashi Shimbo, Takehiko Yamazaki
Estimating the term…
The present inventors identified many nuclear proteins contained in the extract of skin tissue by mass spectrometry, randomly selected multiple partial amino acid sequences of the nuclear proteins, chemically synthesized peptides consisting of the partial amino acid sequences, and examined their activity of mobilizing mesenchymal stem cells. As a result, it was found that these multiple peptides show the activity of mobilizing mesenchymal stem cells into peripheral blood, even though their amino acid sequences are completely different from each other. The inventors also found that fragment peptides of the nuclear proteins have therapeutic effects on diseases characterized by inflammation and abnormalities of the immune system (e.g., inflammatory bowel disease and psoriasis). Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.
A method for mobilizing mesenchymal stem cells to peripheral blood, comprising administering to a subject an effective amount of a peptide consisting of the amino acid sequence that is at least 95% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs:
A method for mobilizing mesenchymal stem cells to peripheral blood, comprising administering to a subject an effective amount of a peptide consisting of the amino acid sequence that is at least 95% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.